FENC

Business Context and Reporting Period

Company: Adherex Technologies Inc. (Note: Request metadata listed "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Filing Type: Form 20-F Transition Report
Reporting Period: Six-month transition period from July 1, 2004, to December 31, 2004.
Context: The Company changed its fiscal year-end from June 30 to December 31. This report covers the transition period required by this change. Adherex is a development-stage biopharmaceutical company focused on cancer therapeutics, chemoprotectants, and chemoenhancers. It has no commercial revenues to date.

Key Financial Metrics (Canadian GAAP)

Note: All figures are in Canadian dollars (CAD) unless otherwise specified. The Company reports under Canadian GAAP; U.S. GAAP net loss for the six months ended Dec 31, 2004, was $(8.3) million due to differences in accounting for acquired intellectual property.

Material Changes vs. Prior Period

• Increased R&D Spending: R&D expenses rose to $4.4 million for the six months ended Dec 31, 2004, compared to $2.0 million for the same period in 2003. This increase was driven by the advancement of the lead candidate ADH-1 (Exherin) into Phase Ib/II trials and preparation for Phase II studies.
• Settlement of Litigation: The Company recorded a one-time charge of $1.6 million for the settlement of litigation with Cadherin Biomedical Inc. (CBI). This was resolved via an amalgamation where Adherex issued approximately 3.2 million shares to CBI shareholders to reacquire non-cancer intellectual property rights.
• Increased G&A Expenses: General and administrative expenses increased to $3.3 million (from $1.5 million in the prior six-month period) due to the establishment of U.S. offices in Research Triangle Park, North Carolina, and increased regulatory compliance costs associated with SEC registration and American Stock Exchange listing.
• Stock-Based Compensation: The Company adopted CICA 3870, requiring the expensing of the fair value of all employee stock options. This resulted in a $0.8 million expense for the period and a retroactive adjustment to retained earnings.

Guidance, Outlook, and Risks

Outlook and Clinical Pipeline

• ADH-1 (Exherin): Concluding Phase I trials; initiated Phase Ib/II trials in Europe (Switzerland/Italy) and planning a second Phase Ib/II in North America. A Phase II program in Canada is expected to commence in Q2 2005.
• STS (Sodium Thiosulfate): Planning a Phase III trial in 2005 to assess reduction of platinum-induced ototoxicity in pediatric patients, potentially in collaboration with the Children's Oncology Group.
• NAC and Mesna: Continuing evaluation of commercial potential based on ongoing Phase I studies.

Liquidity and Capital Resources

As of December 31, 2004, the Company held $21.1 million in cash and cash equivalents. Management believes these funds are sufficient to finance operations until March 31, 2006. However, substantial additional funding will be required to conduct pivotal Phase III trials and commercialize products. Future financing may be sought through equity, debt, or strategic partnerships.

Risk Factors

• Development Risk: Product candidates are in early clinical stages; failure in clinical trials is a significant risk.
• Capital Needs: No revenues to date; reliance on external financing which may not be available on acceptable terms.
• Regulatory Approval: Success depends on obtaining FDA and Health Canada approvals, which are uncertain and costly.
• Intellectual Property: Reliance on licensed technology from McGill, Rutgers, and OHSU; risks of patent challenges or inability to secure necessary licenses.
• PFIC Status: The Company is classified as a Passive Foreign Investment Company (PFIC) under U.S. tax law, which may have adverse tax consequences for U.S. shareholders.

Investor Verification Checklist

• Cash Runway: Verify if the $21.1 million cash balance is sufficient to fund the planned Phase II and Phase III trials through 2006 without dilution.
• Clinical Milestones: Monitor the initiation and results of the Phase Ib/II trials for ADH-1 and the Phase III trial for STS scheduled for 2005.
• Collaboration Agreements: Review the terms of the McGill, Rutgers, and OHSU licenses, specifically milestone payments and royalty obligations.
• Accounting Differences: Note the significant difference between Canadian GAAP and U.S. GAAP regarding the treatment of acquired intellectual property (capitalized vs. expensed as IPRD).
• Share Dilution: Assess the impact of the 3.2 million shares issued to settle the CBI litigation and potential future equity raises.